Zoviduo (aciclovir + hydrocortisone)
Zoviduo is indicated for the treatment of early signs and symptoms of recurrent herpes simplex labialis (HPS) in immunocompetent adults and adolescents (12 years or older) to reduce progression of episodes where cold sores turn into ulcerous lesions.
The combination of hydrocortisone with aciclovir is indented to attenuate inflammation and reduce symptoms.
Compared with aciclovir alone the combination prevented marginally, but significantly, fewer people from developing ulcerous lesions. However, there was no difference in duration or extent of the lesions.
There was no difference between the observed adverse events of Zoviduo and aciclovir.
2 g costs 57.95 DKr and is therefore considerably more expensive than aciclovir alone.
It is IRF’s assessment that Zoviduo is an expensive treatment alternative and we need further studies to confirm that a combination of hydrocortisone with aciclovir is more effective than aciclovir alone.
Zoviduo was marketed January 23rd 2012. It is available without prescription. Zoviduo is not subject to reimbursement.